p. 3993−4003
2476-762X
Vol.14/No.7
p. 4005−4013
2476-762X
Vol.14/No.7
p. 4015−4023
2476-762X
Vol.14/No.7
p. 4025−4032
2476-762X
Vol.14/No.7
p. 4033−4039
2476-762X
Vol.14/No.7
p. 4041−4047
2476-762X
Vol.14/No.7
p. 4049−4052
2476-762X
Vol.14/No.7
p. 4053−4056
2476-762X
Vol.14/No.7
p. 4057−4059
2476-762X
Vol.14/No.7
p. 4061−4066
2476-762X
Vol.14/No.7
p. 4067−4069
2476-762X
Vol.14/No.7
p. 4071−4075
2476-762X
Vol.14/No.7
p. 4077−4082
2476-762X
Vol.14/No.7
p. 4083−4087
2476-762X
Vol.14/No.7
p. 4089−4093
2476-762X
Vol.14/No.7
p. 4095−4099
2476-762X
Vol.14/No.7
0.05). No significant association was detected according toclinical parameters or tumor characteristics; however, a higher frequency of AG genotype was recorded withinpatients with astrocytic or oligoastrocytic tumors. A significant association between AG genotype and gliobilastomamultiforme (GBM) was recorded within the patients with glial tumors (p value=0.048 OR: 1.87 CI% 1.010-3.463). According to tumor characteristics, no statistically significant difference was detected within astrocytic,oligoasltrocytic tumors and oligodentrioglias. However, patients with astrocytic astrocytic or oligoastrocytictumors showed a higher frequency of AG genotype (50%) when compared to those with oligodendrioglial tumors(27.3%). Our results indicate a possible relation between GBM formation and CCDN1 genotype.]]>
p. 4101−4106
2476-762X
Vol.14/No.7
p. 4107−4113
2476-762X
Vol.14/No.7
p. 4115−4119
2476-762X
Vol.14/No.7
p. 4121−4126
2476-762X
Vol.14/No.7
p. 4127−4130
2476-762X
Vol.14/No.7
p. 4131−4134
2476-762X
Vol.14/No.7
p. 4135−4139
2476-762X
Vol.14/No.7
p. 4141−4149
2476-762X
Vol.14/No.7
p. 4151−4155
2476-762X
Vol.14/No.7
p. 4157−4160
2476-762X
Vol.14/No.7
p. 4161−4165
2476-762X
Vol.14/No.7
p. 4167−4175
2476-762X
Vol.14/No.7
p. 4177−4180
2476-762X
Vol.14/No.7
p. 4181−4186
2476-762X
Vol.14/No.7
p. 4187−4193
2476-762X
Vol.14/No.7
p. 4195−4198
2476-762X
Vol.14/No.7
p. 4199−4203
2476-762X
Vol.14/No.7
50ng/mL) and low CEA group (CEA level ≤ 50 ng/mL). Adverse reactions were noted and progression-free survival(PFS) in both groups was recorded after long-term follow-up that ended in December, 2012. Results: There wasno difference between control and non-control groups in CEA level before treatment (P>0.05), whereas serumCEA decreased more markedly lower in the control group after treatment (P<0.01). All patients were dividedinto high CEA group (26) and low CEA group (14) according to serum CEA level. There was no statisticallysignificant difference between two groups in adverse reactions (P>0.05) but the rate in former group was lower.Additionally, survival rates at 9 and 12 months in high CEA group were clearly higher than in the low CEAgroup (P<0.01). Conclusions: Serum CEA level can serve as a biochemical index to evaluate the prognosis withgefitinib treatment for NSCLC.]]>
p. 4205−4208
2476-762X
Vol.14/No.7
0.05). Bcl-2 expression in 14 (66.7%) of the cases oftumor samples and 9 (56.3%) cases of the marginal samples were positive. Comparison of the expression of theBcl-2 gene in histological grade showed that a high expression of Bcl-2 was associated with a high histologicalgrade (p<0.41). Conclusions: Our data suggests that dysregulated Bcl-2 gene expression is potentially involvedin the pathogenesis of breast cancer. Using gene expression analysis may significantly improve our ability forscreening cancer patients and will prove a powerful tool in the diagnosis and prognostic evaluation of the diseasewhilst aiding the cooperative group trials in the Bcl-2 based therapy project.]]>
p. 4209−4214
2476-762X
Vol.14/No.7
p. 4215−4221
2476-762X
Vol.14/No.7
5117 cGy), Dmean (>1487 cGy) and V10-60 (percentage of volume receiving >10 to 60 Gy).The most significant relationship between RT and esophagitis were in Dmax (>5117 cGy) (p=0.002) and percentageof esophageal volume receiving >30 Gy (V30>31%) (p=0.008) in the logistic regression analysis. Conclusions: Themaximum dose esophagus greater than 5117 cGy and approximately one third (31%) of the esophageal volumereceiving >30 Gy was the most statistically significant predictive factor associated with esophagitis due to RT.]]>
p. 4223−4228
2476-762X
Vol.14/No.7
p. 4229−4233
2476-762X
Vol.14/No.7
p. 4235−4238
2476-762X
Vol.14/No.7
p. 4239−4242
2476-762X
Vol.14/No.7
p. 4243−4247
2476-762X
Vol.14/No.7
p. 4249−4254
2476-762X
Vol.14/No.7
p. 4255−4259
2476-762X
Vol.14/No.7
p. 4261−4265
2476-762X
Vol.14/No.7
p. 4267−4271
2476-762X
Vol.14/No.7
p. 4273−4278
2476-762X
Vol.14/No.7
p. 4279−4282
2476-762X
Vol.14/No.7
p. 4283−4287
2476-762X
Vol.14/No.7
30 ng/mL were classified as CEA Group 3. Similarly the patients with a CA 19-9 level <35 U/mL were classified as CA19-9 Group 1, with 35-100 U/mL as Group 2 and with >100 U/mL as Group and 3. TNM stages and histologicgrades were noted according to histopathological reports. Patients with a TNM grade 0 or 1 were classified asGroup A, TNM grade 2 patients constituted Group B and TNM grade 3 and 4 patients constituted Group C.Demographic characteristics, tumor locations and blood types of the patients were all recorded and these datawere compared with the preoperative CEA and CA19-9 values. Results: A significant correlation between CA19-9 levels (>100 U/mL) and TNM stage (in advanced stages) was determined. We also determined a significantcorrelation between TNM stages and positive vlaues for both CEA and CA 19-9 in colorectal and gastric cancerpatients. In comparison between CEA and CA 19-9 levels and age, gender, tumor location, ABO blood group,and tumor histologic grade, no significant correlation was found. Conclusions: Positive levels of both CEA andCA 19-9 can be considered to indicate an advanced stage in colorectal and gastric cancer patients.]]>
p. 4289−4294
2476-762X
Vol.14/No.7
p. 4295−4299
2476-762X
Vol.14/No.7
G Polymorphism was Associated with an Increased Risk of Gastric Cardiac Adenocarcinoma in a Chinese Population]]>
G, BCL2 rs12454712 T>C, FAS rs2234767 G>A, FASL/FASLG rs763110 C>T,ERBB2 rs1136201 A>G and VEGFR2/KDR rs11941492 C>T on the development of GCA. A total of 243 GCAcases and 476 controls were recruited for the study and genotypes were determined using a custom-by-design48-Plex SNPscanTM Kit. Results: The BCL2 rs17757541 C>G polymorphism was associated with increased riskof GCA. However, there was no significant associations with the other five SNPs. Stratified analyses indicateda significantly increased risk of GCA associated with the BCL2 rs17757541 C>G polymorphism among males,older patients and those with a history of smoking or drinking. Conclusion: These findings indicated that thefunctional polymorphism BCL2 rs17757541 C>G might contribute to GCA susceptibility. However, our resultswere limited by small sample size. Future larger studies are required to confirm our current findings.]]>
p. 4301−4306
2476-762X
Vol.14/No.7
p. 4307−4312
2476-762X
Vol.14/No.7
p. 4313−4318
2476-762X
Vol.14/No.7
p. 4319−4323
2476-762X
Vol.14/No.7
p. 4325−4328
2476-762X
Vol.14/No.7
p. 4329−4334
2476-762X
Vol.14/No.7
p. 4335−4338
2476-762X
Vol.14/No.7
p. 4339−4345
2476-762X
Vol.14/No.7
p. 4347−4352
2476-762X
Vol.14/No.7
30%) was associated with decreased HER2neu positivity as comparedto intermediate Ki67 (16-30%). The same trend was established with lymph node metastasis. Conclusion: Ourstudy indicates that with high grade tumors, clinical utility of ki67 is greater in combination with other prognosticmarkers because we found that tumors with Ki67 higher than 30% have better prognostic profile comparedto tumors with intermediate Ki67 level, as reflected by slightly lower frequency of lymph node metastasis andHER2neu expression. Therefore we suggest that Ki67 index should be categorized into high, intermediate andlow groups when considering adjuvant chemotherapy and prognostic stratification.]]>
p. 4353−4358
2476-762X
Vol.14/No.7
p. 4359−4363
2476-762X
Vol.14/No.7
p. 4365−4368
2476-762X
Vol.14/No.7
p. 4369−4371
2476-762X
Vol.14/No.7
p. 4373−4377
2476-762X
Vol.14/No.7
p. 4379−4386
2476-762X
Vol.14/No.7
p. 4387−4392
2476-762X
Vol.14/No.7
p. 4393−4398
2476-762X
Vol.14/No.7
p. 4399−4402
2476-762X
Vol.14/No.7
p. 4403−4408
2476-762X
Vol.14/No.7
p. 4409−4413
2476-762X
Vol.14/No.7
p. 4415−4419
2476-762X
Vol.14/No.7
p. 4421−4426
2476-762X
Vol.14/No.7
p. 4427−4433
2476-762X
Vol.14/No.7
p. 4435−4440
2476-762X
Vol.14/No.7
p. 4441−4446
2476-762X
Vol.14/No.7
p. 4447−4453
2476-762X
Vol.14/No.7
p. 4455−4457
2476-762X
Vol.14/No.7
p. 4459−4459
2476-762X
Vol.14/No.7